Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta

Bone

Volumn 66, Issue , 2014, Pages 182-188

  Roschger, Andreas ^a   Roschger, Paul ^a   Keplingter, Petra ^a   Klaushofer, Klaus ^a   Abdullah, Sami ^b,d   Kneissel, Michaela ^c   Rauch, Frank ^b,d  

^a HANUSCH HOSPITAL   (Austria)

^b SHRINERS HOSPITAL FOR CHILDREN   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bone formation; Osteogenesis imperfecta; Quantitative backscattered electron imaging; Sclerostin

Indexed keywords

ALKALINE PHOSPHATASE; ANTIBODY; BPS 804; CALCIUM ION; CARBOXY TERMINAL TELOPEPTIDE; PROCOLLAGEN; PROCOLLAGEN TYPE 1 N PROPEPTIDE; SCLEROSTIN; SCLEROSTIN ANTIBODY; UNCLASSIFIED DRUG; GLYCOPROTEIN; SOST PROTEIN, MOUSE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE LENGTH; BONE MASS; BONE MINERALIZATION; CONTROLLED STUDY; CORTICAL THICKNESS (BONE); DISEASE SEVERITY; DRUG EFFECT; ENZYME ACTIVITY; FEMUR; GENOTYPE; IMAGING; IMMUNOTHERAPY; LUMBAR VERTEBRA; MALE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; QUANTITATIVE BACKSCATTERED ELECTRON IMAGING; TRABECULAR BONE; TREATMENT DURATION; WILD TYPE; ANIMAL; BLOOD; BODY WEIGHT; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; RADIOGRAPHY;

ANIMALS; ANTIBODIES; BIOMECHANICAL PHENOMENA; BODY WEIGHT; DISEASE MODELS, ANIMAL; FEMUR; GLYCOPROTEINS; LUMBAR VERTEBRAE; MALE; MICE; OSTEOGENESIS IMPERFECTA; X-RAY MICROTOMOGRAPHY;

EID: 84903529224     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.06.015     Document Type: Article

References (28)

1. Forlino A., Cabral W.A., Barnes A.M., Marini J.C. New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol 2011, 7:540-557.
2. Rauch F., Glorieux F.H. Osteogenesis imperfecta. Lancet 2004, 363:1377-1385.
3. Baron R., Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 2013, 19:179-192.
4. Cui Y., Niziolek P.J., MacDonald B.T., Zylstra C.R., Alenina N., Robinson D.R., et al. Lrp5 functions in bone to regulate bone mass. Nat Med 2011, 17:684-691.
5. McClung M.R., Grauer A., Boonen S., Bolognese M.A., Brown J.P., Diez-Perez A., et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014, 370:412-420.
6. Ominsky M.S., Vlasseros F., Jolette J., Smith S.Y., Stouch B., Doellgast G., et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010, 25:948-959.
7. Sinder B.P., Eddy M.M., Ominsky M.S., Caird M.S., Marini J.C., Kozloff K.M. Sclerostin antibody improves skeletal parameters in a Brtl/+mouse model of osteogenesis imperfecta. J Bone Miner Res 2013, 28:73-80.
8. Jacobsen C.M., Barber L.A., Ayturk U.M., Roberts H.J., Deal L.E., Schwartz M.A., et al. Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta. J Bone Miner Res 2014, 10.1002/jbmr.2198.
9. Sinder B.P., White L.E., Salemi J.D., Ominsky M.S., Caird M.S., Marini J.C., et al. Adult Brtl/+mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength. Osteoporos Int 2014, 10.1007/s00198-014-2737-y.
10. Chen F., Guo R., Itoh S., Moreno L., Rosenthal E., Zappitelli T., et al. First mouse model for combined osteogenesis imperfecta and Ehlers-Danlos syndrome. J Bone Miner Res 2014, 29:1421-1423.
11. Ponsel D., Neugebauer J., Ladetzki-Baehs K., Tissot K. High affinity, developability and functional size: the holy grail of combinatorial antibody library generation. Molecules 2011, 16:3675-3700.
12. Rothe C., Urlinger S., Lohning C., Prassler J., Stark Y., Jager U., et al. The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies. J Mol Biol 2008, 376:1182-1200.
13. Dempster D.W., Compston J.E., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2013, 28:2-17.
14. Roschger P., Fratzl P., Eschberger J., Klaushofer K. Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies. Bone 1998, 23:319-326.
15. Fratzl-Zelman N., Morello R., Lee B., Rauch F., Glorieux F.H., Misof B.M., et al. CRTAP deficiency leads to abnormally high bone matrix mineralization in a murine model and in children with osteogenesis imperfecta type VII. Bone 2010, 46:820-826.
16. Koivula M.K., Richardson J., Leino A., Valleala H., Griffiths K., Barnes A., et al. Validation of an automated intact N-terminal propeptide of type I procollagen (PINP) assay. Clin Biochem 2010, 43:1453-1457.
17. Chubb S.A. Measurement of C-terminal telopeptide of type I collagen (CTX) in serum. Clin Biochem 2012, 45:928-935.
18. Rauch F., Travers R., Parfitt A.M., Glorieux F.H. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone 2000, 26:581-589.
19. Uveges T.E., Collin-Osdoby P., Cabral W.A., Ledgard F., Goldberg L., Bergwitz C., et al. Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors. J Bone Miner Res 2008, 23:1983-1994.
20. Uveges T.E., Kozloff K.M., Ty J.M., Ledgard F., Raggio C.L., Gronowicz G., et al. Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation. J Bone Miner Res 2009, 24:849-859.
21. Weber M., Roschger P., Fratzl-Zelman N., Schoberl T., Rauch F., Glorieux F.H., et al. Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta. Bone 2006, 39:616-622.
22. Roschger P., Fratzl-Zelman N., Misof B.M., Glorieux F.H., Klaushofer K., Rauch F. Evidence that abnormal high bone mineralization in growing children with osteogenesis imperfecta is not associated with specific collagen mutations. Calcif Tissue Int 2008, 82:263-270.
23. Fratzl-Zelman N., Schmidt I., Roschger P., Glorieux F.H., Klaushofer K., Fratzl P., et al. Mineral particle size in children with osteogenesis imperfecta type I is not increased independently of specific collagen mutations. Bone 2014, 60:122-128.
24. Grabner B., Landis W.J., Roschger P., Rinnerthaler S., Peterlik H., Klaushofer K., et al. Age- and genotype-dependence of bone material properties in the osteogenesis imperfecta murine model (oim). Bone 2001, 29:453-457.
25. Misof B.M., Roschger P., Baldini T., Raggio C.L., Zraick V., Root L., et al. Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse. Bone 2005, 36:150-158.
26. Palomo T., Glorieux F.H., Rauch F. Circulating sclerostin in children and young adults with heritable bone disorders. J Clin Endocrinol Metab 2014, 99:E920-E925.
27. Kocijan R., Muschitz C., Fahrleitner-Pammer A., Amrein K., Pietschmann P., Haschka J., et al. Serum sclerostin levels are decreased in adult patients with different types of osteogenesis imperfecta. J Clin Endocrinol Metab 2014, 99:E311-E319.
28. Orwoll E.S., Shapiro J., Veith S., Wang Y., Lapidus J., Vanek C., et al. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest 2014, 124:491-498.